...
search icon
plx-img

Protalix Biotherapeutics Inc Share Price

PLX
ASQ
$2.97
+$0.11
(3.85%)
1D
Industry: Biotechnology Sector: Health Care

Protalix Biotherapeutics Inc Analyst Forecast

Protalix Biotherapeutics Inc Share Price Chart

Protalix Biotherapeutics Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$230.00M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
35.75
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.20M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.22
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.32 L
$3.1 H
$2.97

About Protalix Biotherapeutics Inc, Common Stock

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey. more

Industry: BiotechnologySector: Health Care

Protalix Biotherapeutics Inc Stock Returns

Time FramePLXSectorS&P500
1-Week Return2.77%-1.08%-1.38%
1-Month Return47.03%-0.47%-1.81%
3-Month Return53.89%2.13%1.38%
6-Month Return84.47%17.04%5.68%
1-Year Return11.65%6.56%11.74%
3-Year Return92.86%16.78%65.15%
5-Year Return-37.47%34.34%73.68%
10-Year Return-62.87%137.88%260.03%

Protalix Biotherapeutics Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue62.90M38.35M47.64M65.49M53.40M[{"date":"2020-12-31","value":96.04,"profit":true},{"date":"2021-12-31","value":58.55,"profit":true},{"date":"2022-12-31","value":72.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":81.53,"profit":true}]
Cost of Revenue10.87M16.35M19.59M22.98M24.32M[{"date":"2020-12-31","value":44.71,"profit":true},{"date":"2021-12-31","value":67.23,"profit":true},{"date":"2022-12-31","value":80.56,"profit":true},{"date":"2023-12-31","value":94.5,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit52.02M22.00M28.05M42.51M29.08M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":42.29,"profit":true},{"date":"2022-12-31","value":53.91,"profit":true},{"date":"2023-12-31","value":81.71,"profit":true},{"date":"2024-12-31","value":55.9,"profit":true}]
Gross Margin82.71%57.37%58.87%64.91%54.46%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":69.36,"profit":true},{"date":"2022-12-31","value":71.18,"profit":true},{"date":"2023-12-31","value":78.48,"profit":true},{"date":"2024-12-31","value":65.84,"profit":true}]
Operating Expenses49.31M42.46M41.06M32.05M25.16M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":86.11,"profit":true},{"date":"2022-12-31","value":83.26,"profit":true},{"date":"2023-12-31","value":64.99,"profit":true},{"date":"2024-12-31","value":51.03,"profit":true}]
Operating Income2.71M(20.46M)(13.01M)10.46M3.92M[{"date":"2020-12-31","value":25.91,"profit":true},{"date":"2021-12-31","value":-195.62,"profit":false},{"date":"2022-12-31","value":-124.42,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":37.45,"profit":true}]
Total Non-Operating Income/Expense(18.47M)(14.24M)(2.77M)(3.79M)474.00K[{"date":"2020-12-31","value":-3895.78,"profit":false},{"date":"2021-12-31","value":-3004.22,"profit":false},{"date":"2022-12-31","value":-583.54,"profit":false},{"date":"2023-12-31","value":-799.16,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(6.52M)(27.58M)(14.40M)8.57M4.15M[{"date":"2020-12-31","value":-76.15,"profit":false},{"date":"2021-12-31","value":-321.99,"profit":false},{"date":"2022-12-31","value":-168.07,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":48.49,"profit":true}]
Income Taxes8.37M6.40M530.00K254.00K1.22M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":76.51,"profit":true},{"date":"2022-12-31","value":6.33,"profit":true},{"date":"2023-12-31","value":3.04,"profit":true},{"date":"2024-12-31","value":14.6,"profit":true}]
Income After Taxes(14.89M)(33.98M)(14.93M)8.31M2.93M[{"date":"2020-12-31","value":-179.16,"profit":false},{"date":"2021-12-31","value":-408.87,"profit":false},{"date":"2022-12-31","value":-179.58,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":35.27,"profit":true}]
Income From Continuous Operations(6.52M)(27.58M)(14.93M)8.31M2.93M[{"date":"2020-12-31","value":-78.48,"profit":false},{"date":"2021-12-31","value":-331.83,"profit":false},{"date":"2022-12-31","value":-179.58,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":35.27,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(6.52M)(27.58M)(14.93M)8.31M2.93M[{"date":"2020-12-31","value":-78.48,"profit":false},{"date":"2021-12-31","value":-331.83,"profit":false},{"date":"2022-12-31","value":-179.58,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":35.27,"profit":true}]
EPS (Diluted)(0.16)(0.63)(0.30)0.050.03[{"date":"2020-12-31","value":-320,"profit":false},{"date":"2021-12-31","value":-1260,"profit":false},{"date":"2022-12-31","value":-600,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":60,"profit":true}]

Protalix Biotherapeutics Inc Ratios

Protalix Biotherapeutics Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

PLX
Cash Ratio 1.34
Current Ratio 3.03
Quick Ratio 2.06

Protalix Biotherapeutics Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

PLX
ROA (LTM) 5.53%
ROE (LTM) 12.64%

Protalix Biotherapeutics Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

PLX
Debt Ratio Lower is generally better. Negative is bad. 0.36
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.64

Protalix Biotherapeutics Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

PLX
Trailing PE 35.75
Forward PE 40.82
P/S (TTM) 3.72
P/B 4.35
Price/FCF NM
EV/R 3.38
EV/Ebitda 23.97
PEG NM

FAQs

What is Protalix Biotherapeutics Inc share price today?

Protalix Biotherapeutics Inc (PLX) share price today is $2.97

Can Indians buy Protalix Biotherapeutics Inc shares?

Yes, Indians can buy shares of Protalix Biotherapeutics Inc (PLX) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PLX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Protalix Biotherapeutics Inc be purchased?

Yes, you can purchase fractional shares of Protalix Biotherapeutics Inc (PLX) via the Vested app. You can start investing in Protalix Biotherapeutics Inc (PLX) with a minimum investment of $1.

How to invest in Protalix Biotherapeutics Inc shares from India?

You can invest in shares of Protalix Biotherapeutics Inc (PLX) via Vested in three simple steps:

  • Click on Sign Up or Invest in PLX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Protalix Biotherapeutics Inc shares
What is Protalix Biotherapeutics Inc 52-week high and low stock price?

The 52-week high price of Protalix Biotherapeutics Inc (PLX) is $3.1. The 52-week low price of Protalix Biotherapeutics Inc (PLX) is $1.32.

What is Protalix Biotherapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Protalix Biotherapeutics Inc (PLX) is 35.75

What is Protalix Biotherapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Protalix Biotherapeutics Inc (PLX) is 4.35

What is Protalix Biotherapeutics Inc dividend yield?

The dividend yield of Protalix Biotherapeutics Inc (PLX) is 0.00%

What is the Market Cap of Protalix Biotherapeutics Inc?

The market capitalization of Protalix Biotherapeutics Inc (PLX) is $230.00M

What is Protalix Biotherapeutics Inc's stock symbol?

The stock symbol (or ticker) of Protalix Biotherapeutics Inc is PLX

How Can Investors Use Protalix Biotherapeutics Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Protalix Biotherapeutics Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Protalix Biotherapeutics Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Protalix Biotherapeutics Inc shares for Indian investors?

When investing in Protalix Biotherapeutics Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Protalix Biotherapeutics Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Protalix Biotherapeutics Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Protalix Biotherapeutics Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Protalix Biotherapeutics Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top